alpha-En (ALPE) 10-K 2 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	alpha-En Corp
Entity Central Index Key	1,023,298
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 18,100
Entity Common Stock, Shares Outstanding		32,645,756
Trading Symbol	ALPE
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash	$ 562	$ 442
Prepaid expenses		91
Restricted cash	15	100
Total current assets	577	633
Long-term deposit	35	50
Property and equipment, net	501	541
Total assets	1,113	1,224
Current liabilities
Accounts payable and accrued expenses	1,103	964
Advances from related parties	308	78
Total current liabilities	1,411	1,042
Total liabilities	1,411	1,042
Series A Preferred stock par value $0.01: 2,000,000 shares authorized; 1,935 shares issued and outstanding as of December 31, 2017; aggregate liquidation preference of $1,935	1,935
COMMITMENTS AND CONTINGENCIES
Stockholders' (deficit) equity:
Common stock par value $0.01: 57,000,000 shares authorized; 33,350,506 shares and 33,282,089 shares issued and 32,635,756 and 32,567,339 shares outstanding at December 31, 2017 and 2016, respectively	334	333
Additional paid-in capital	18,482	13,987
Treasury stock at cost: 714,750 shares as of December 31, 2017 and 2016	(69)	(69)
Accumulated deficit	(20,276)	(13,749)
Stockholders' (deficit) equity attributed to alpha-En Corporation stockholders	(1,529)	502
Non-controlling interest	(704)	(320)
Total stockholders' (deficit) equity	(2,233)	182
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY AND TEMPORARY EQUITY	1,113	1,224
Common Class B [Member]
Stockholders' (deficit) equity:
Common stock par value $0.01: 57,000,000 shares authorized; 33,350,506 shares and 33,282,089 shares issued and 32,635,756 and 32,567,339 shares outstanding at December 31, 2017 and 2016, respectively

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par or stated value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	1,935
Preferred stock, shares outstanding	1,935
Preferred stock, liquidation preference	$ 1,935
Common stock, par or stated value per share	$ 0.01	$ 0.01
Common stock, shares authorized	57,000,000	57,000,000
Common stock, shares, issued	33,350,506	33,282,089
Common stock, shares, outstanding	32,635,756	32,567,339
Treasury stock, shares	714,750	714,750
Common Class B [Member]
Common stock, par or stated value per share
Common stock, shares authorized	1,000,000	1,000,000
Common stock, shares, issued
Common stock, shares, outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating expenses
General and administrative	$ 4,367	$ 1,666
Legal and professional fees	537	695
Research and development	1,927	1,436
Total operating expenses	6,831	3,797
Other income (loss)
Loss on extinguishment of accounts payable	(82)
Interest income	2
Total other loss	(80)
Net loss	(6,911)	(3,797)
Less: net loss attributable to non-controlling interest	(384)	(217)
Net loss attributable to controlling interest	(6,527)	(3,580)
Less: Dividends accrued on preferred stock	(115)
Less: Deemed dividend on Series A preferred stock	(649)
Less: Deemed dividend - beneficial conversion feature on preferred stock	(807)
Less: Deemed dividend - issuance of common shares under anti-dilution provisions		(116)
Less: Deemed dividend - inducement to exercise warrants		(378)
Net loss attributable to alpha-En Corporation common stockholders	$ (8,098)	$ (4,074)
Net loss per share attributable to alpha-En Corporation common stockholders
Basic and diluted	$ (0.24)	$ (0.12)
Weighted average shares outstanding:
Basic and diluted	33,312,970	33,347,318

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2015	$ 322	$ 10,705	$ (69)	$ (10,169)	$ (98)	$ 691
Balance, shares at Dec. 31, 2015	32,235,525		714,750
Non-employee options exercised for cash	$ 1	10				11
Non-employee options exercised for cash, shares	100,000
Warrants exercised for cash	$ 2	213				215
Warrants exercised for cash, shares	221,875
Stock based compensation (shares and options)	$ 7	1,575				1,582
Stock based compensation (shares and options), Shares	650,000
Issuance of common stock and warrants in a private placement	$ 14	1,391				1,405
Issuance of common stock and warrants in a private placement, shares	1,394,689
Shares cancellation	$ (14)	14
Shares cancellation, Shares	(1,420,000)
Shares issued due to anti-dilution	$ 1	115				116
Shares issued due to anti-dilution, Shares	100,000
Deemed dividend - inducement to exercise warrants		(116)				(116)
Issuance of subsidiary common stock for services		80			(5)	75
Warrants granted as inducement to exercise warrants		378				378
Deemed dividend - inducement to exercise warrants		(378)				(378)
Common stock and warrants issued for extinguishment of accounts payable
Vested options exchanged for cash
Net loss				(3,580)	(217)	(3,797)
Balance at Dec. 31, 2016	$ 333	13,987	$ (69)	(13,749)	(320)	182
Balance, shares at Dec. 31, 2016	33,282,089		714,750
Stock based compensation (shares and options)		4,189				4,189
Stock based compensation (shares and options), Shares
Deemed dividend - inducement to exercise warrants
Issuance of subsidiary common stock for services
Warrants granted as inducement to exercise warrants		249				249
Deemed dividend - inducement to exercise warrants
Warrant issued for services			249			249
Common stock and warrants issued for extinguishment of accounts payable	$ 1	191				192
Common stock and warrants issued for extinguishment of accounts payable, shares	62,417
Options exercised for cash		6				6
Options exercised for cash, shares	6,000
Issuance of warrants to purchase common stock associated with preferred stock offering		649				649
Deemed dividend on Series A preferred stock		(649)				(649)
Beneficial conversion feature of Series A preferred stock		807				807
Deemed dividends related to beneficial conversion feature of Series A preferred stock		(807)				(807)
Vested options exchanged for cash		(25)				25
Accrued Series A dividends		(115)				(115)
Net loss				(6,527)	(384)	(6,911)
Balance at Dec. 31, 2017	$ 334	$ 18,482	$ (69)	$ (20,276)	$ (704)	$ (2,233)
Balance, shares at Dec. 31, 2017	33,350,506		714,750

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ (6,911)	$ (3,797)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	65	12
Stock-based compensation	4,189	1,582
Warrant issued for services	249
Loss on extinguishment of accounts payable	82
Issuance of subsidiary common stock for services		75
Changes in operating assets and liabilities of business, net of acquisitions:
Prepaid expenses	91	210
Due from related parties		61
Accounts payable and accrued expenses	249	384
Net cash used in operating activities	(1,986)	(1,473)
Cash flows from investing activities
Release of restricted cash and long term deposit	100	(150)
Purchase of fixed assets	(25)	(312)
Net cash provided by (used in) investing activities	75	(462)
Cash flows from financing activities
Proceeds from issuance of preferred stock and warrants	1,670	1,405
Options exercised for cash	6	11
Vested options exchanged for cash	(25)
Warrants exercised for cash		215
Advances from related parties	412	86
Repayments of advances from related parties	(32)	(70)
Net cash provided by financing activities	2,031	1,647
Net increase (decrease) in cash	120	(288)
Cash at beginning of period	442	730
Cash at end of period	562	442
Non cash financing and investing activities:
Beneficial conversion feature of Series A preferred stock	807
Deemed dividends related to beneficial conversion feature of Series A preferred stock	807
Deemed dividend on Series A preferred stock	649
Deemed dividend related to issuance of warrants as inducement to exercise existing warrants		378
Deemed dividend related to issuance of common shares under anti-dilution provisions		116
Purchase of property and equipment included in accounts payable and accrued expenses		239
Accrued Series A dividends	115
Conversion of advances from related parties to preferred stock	150
Common stock and warrants issued for extinguishment of accounts payable	192
Issuance of restricted stock to employee		7
Shares cancellation		$ 14

Organization and Operations

Organization and Operations	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Operations	Note 1 - Organization and Operations alpha-En Corporation (together with its subsidiaries, the “Company”) was incorporated in Delaware on March 7, 1997 Since 2008, the focus of the Company’s business has been developing new technologies for manufacturing highly pure lithium metal, a raw material for use in lightweight, high energy density batteries, in an environmentally friendly manner for commercial purposes. In 2013, the Company invented a new process for the production of highly pure lithium metal and associated products at room temperature. The Company subsequently broadened our focus to develop products and processes derived from the Company’s new core proprietary technology, including battery components and compounds of lithium. Formation of Majority-Owned Subsidiary In September 2014, alpha-En Corporation formed Clean Lithium Corporation (“CLC”) under the laws of New York State as a wholly owned subsidiary with a nominal share capital of $100,000. Following the sale of CLC’s shares, the ownership is as follows: Stockholder Shares Percentage alpha-En Corporation 9,095,000 90.95 % Non-controlling interests 905,000 9.05 % Total: 10,000,000 100.00 % Amended and Restated Certificate of Incorporation On March 29, 2017 the Board of Directors of the Company and a subset of the Company’s stockholders representing in excess of 75% of the Company’s currently issued and outstanding voting stock approved of the amendment and restatement of the Company’s Certificate of Incorporation (the “Restated Certificate”) to make certain corporate governance updates and to increase the authorized capital stock of the Company to 60,000,000 shares, of which 57,000,000 are shares of Common Stock, par value $0.01 per share, 1,000,000 are shares of Class B Common Stock, par value $0.01 per share and 2,000,000 are shares of preferred stock, par value $0.01 per share. The Company filed a definitive information statement on Schedule 14C with the Securities and Exchange Commission on June 1, 2017 describing the changes in the Restated Certificate. The Restated Certificate was filed with the Secretary of State for the State of Delaware and became effective on June 30, 2017. On February 8, 2018 the Company filed with the Secretary of State of the State of Delaware an amended and restated certificate of incorporation increasing the authorized number of preferred shares designated as series A preferred from 2,000 to 5,000.

Going Concern and Liquidity

Going Concern and Liquidity	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Liquidity	Note 2 - Going Concern and Liquidity The Company’s consolidated financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the consolidated financial statements, the Company had an accumulated deficit of approximately $20.3 million and negative working capital of $834,000 at December 31, 2017. For the years ending December 31, 2017 and 2016, the Company had a net loss of approximately $6.9 million and $3.8 million and net cash used in operating activities of approximately $2.0 million and $1.5 million for the years ended December 31, 2017 and 2016, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is attempting to further develop the intellectual property associated with its technology; broaden its patent portfolio; scale up our production of various products; and begin generating revenue; however, the Company’s cash position is not sufficient to support its daily operations for the foreseeable future. While the Company believes in the viability of its technology and in its ability to raise additional funds by way of a public or private offering, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon its ability to raise additional funds by way of a public or private offering and its ability to further develop its technology and generate sufficient revenue. The consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant and Critical Accoun

Significant and Critical Accounting Policies and Practices	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant and Critical Accounting Policies and Practices	Note 3 - Significant and Critical Accounting Policies and Practices Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company’s consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated. Use of Estimates The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value used in estimating the value of warrants, stock-based compensation, accrued expenses and provisions for income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Fair Value Measurement The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The carrying amounts of cash accounts payable and accrued expenses and advances from related parties approximate fair value as these accounts are largely current and short term in nature. Cash As of December 31, 2017 and 2016, substantially all of the Company’s cash was held by major financial institutions and the balance at certain times may exceed the maximum amount insured by the Federal Deposits Insurance Corporation. However, the Company has not experienced losses on these accounts and management believes that the Company is not exposed to significant risks on such accounts. Property and Equipment Lab equipment, leasehold improvements and office equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset, generally three years. Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. There were no indicators of impairment for long-lived assets during the years ended December 31, 2017 and 2016. Fair Value of Preferred Stock The fair value of Preferred stock was estimated based upon equivalent common shares that Preferred Stock could have been converted into at the closing price on the purchase date. Convertible Financial Instruments The Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument. Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares. Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations, consultants, the cost of acquiring and manufacturing research trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit. Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options, unvested shares of restricted stock and outstanding common stock purchase warrants because their effect would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at December 31, 2017 and 2016 are as follows: As of December 31, 2017 2016 Warrants to purchase common stock 4,744,292 3,271,875 Options to purchase common stock 8,874,000 4,530,000 Preferred stock to exchange common stock 1,106,807 - Total 14,725,099 7,801,875 Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests. Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Updates (the “ASU”) 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments,

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 - Property and Equipment The components of property and equipment as of December 31, 2017 and 2016, at cost are (dollars in thousands): Useful Life (Years) December 31, 2017 December 31, 2016 Lab equipment 3 $ 173 $ 173 Office furniture and equipment 3 31 12 Leasehold improvement 7 374 368 Gross property and equipment 578 553 Less: Accumulated depreciation and amortization (77 ) (12 ) Property and equipment, net $ 501 $ 541 The Company’s depreciation expense for the years ended December 31, 2017 and 2016 was $65,000 and $12,000, respectively.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 5 - Related Party Transactions Advances from Related Parties From time to time, stockholders of the Company advance funds to the Company for working capital purposes. Those advances are unsecured, non-interest bearing and due on demand. During the year ended December 31, 2017, the Company borrowed $150,000 from Steven M. Payne, $100,000 from Jerome I. Feldman, $150,000 from Jim Kilman and $12,000 from Steven M. Fludder and repaid $32,000 in advances and $150,000 was converted into 150 shares of preferred stock. As of December 31, 2017 and 2016, the outstanding amount of the advances from related parties was $308,000 and $78,000, respectively. Free Office Space During 2015 and through September 2016, the Company was provided office space by its Chairman of the Board at no cost. Management determined that such cost was nominal and did not recognize the rent expense in its consolidated financial statements. Restricted Stock Grant to Chief Executive Officer and Associated Withholding Payments During the year ended December 31, 2016, Steven M. Fludder, the former Chief Executive Officer, paid the Company a withholding tax obligation of $198,000 related to the grant of restricted stock in 2015. As of December 31, 2017, the Company had a remaining liability of approximately $57,000. Appointment of Chief Financial Officer On February 23, 2017, the Board of Directors of the Company appointed Nathan Wasserman to become Chief Financial Officer of the Company, effective as of March 1, 2017. Pursuant to a term sheet dated February 27, 2017, Mr. Wasserman agreed to serve as the Company’s Chief Financial Officer for an initial term of three years. The Company granted Mr. Wasserman stock options to purchase a total of 500,000 shares of common stock at an exercise price of $1.10 per share, of which 150,000 vested immediately, 150,000 will vest in his second year of service and 200,000 will vest in his third year of service. Mr. Wasserman receives a starting salary of $5,000 per month. Appointment of Chief Executive Officer On November 1, 2017, the Company appointed Sam Pitroda to serve as Chief Executive Officer, succeeding Steve Fludder who submitted his resignation as Chief Executive Officer to the Company on October 30, 2017, with such resignation to be effective as of November 1, 2017. Mr. Fludder’s resignation and Mr. Pitroda’s appointment were each effective as of November 1, 2017. Mr. Fludder will continue to support the Company in a consulting capacity. Issue shares of subsidiary During the year ended December 31, 2016, the company also issued 75,000 shares of its subsidiary, CLC, to a consultant, who is also a stockholder for the service provided, and the shares were valued at $1.00 per share based upon the estimated fair value on the date the shares were issued. A related expense of $75,000 was recorded during the year ended December 31, 2016.

Temporary Equity

Temporary Equity	12 Months Ended
	Dec. 31, 2017
Temporary Equity [Abstract]
Temporary Equity	Note 6 - Temporary Equity Series A Preferred Stock The following table summarizes the Company’s Series A Preferred Stock activities for the year ended December 31, 2017 (dollars in thousands): Series A Preferred Stock Shares Amount Total temporary equity as of December 31, 2016 - $ - Proceeds from sale of Series A preferred stock 1,670 1,670 Conversion of advances into preferred stock 150 150 Beneficial conversion feature of Series A preferred stock - (807 ) Deemed dividends related to beneficial conversion feature of Series A preferred stock - 807 Accrued Series A dividends 115 115 Deemed dividend on Series A preferred stock - 649 Fair Value of common stock warrant issued with Series A preferred stock - (649 ) Total temporary equity as of December 31, 2017 1,935 $ 1,935 On May 17, 2017, the Company entered into a preferred stock purchase agreement (“Stock Purchase Agreement”) with several accredited and institutional investors, pursuant to which the Company agreed to issue and sell in a private placement 1,820 shares of its newly designated Series A Preferred Stock, par value $0.01 per share (“Series A Preferred”), as well as 910,000 warrants to purchase the Company’s common stock, par value $0.01 per share (“Common Stock”), at a purchase price of $1,000 per share, for total gross proceeds of $1.82 million (including previous advances from related parties). The warrants have a 5-year term and an exercise price of $2.00. Steven M. Payne, Jerome I. Feldman and Jim Kilman each converted $50,000 advances into preferred stock. The Series A Preferred is entitled to accrue cumulative dividends at a rate equal to 10.0% simple interest per annum on the original issue price of $1,000 per share (the “Original Issue Price”). Accrued dividends will be payable quarterly based on a 365-day year and may be paid in cash or in additional shares of Series A Preferred. Each share of Series A Preferred is convertible into 572 shares of Common Stock, subject to customary increases or decreases for stock splits, stock dividends recapitalizations and the like, and may be converted to Common Stock at any time after issuance at the option of a holder. The Company will have the right, at the Company’s option, to redeem all or a portion of the shares of Series A Preferred Stock at any time or times after the one year anniversary of the Issuance Date of such Series A Preferred Stock, at a price per share (the “Redemption Price”) equal to the sum of the following (without duplication): (a) the Original Issue Price, plus (b) any accrued but unpaid Dividends. Upon any liquidation, dissolution or winding up of the Company, liquidation of the Company’s assets will be made in the following order of priority: (a) first, payment or provision for payment of debts and other liabilities; (b) second, payment to the holders of Series A Preferred an amount with respect to each share of Series A Preferred equal to the Original Issue Price, plus any accrued but unpaid Dividends thereon; and (c) third, payment to the holders of Common Stock. Except as required by applicable law or as set forth herein, the holders of shares of Series A Preferred Stock will vote together with the holders of shares of Common Stock and not as a separate class. Each share of Series A Preferred Stock will have a number of votes equal to the number of shares of Common Stock then issuable upon conversion of such share of Series A Preferred Stock. The Series A Preferred Stock is being classified as temporary equity because it has redemption features that are outside of the Company’s control upon certain triggering events, such as a deemed liquidation event. A “Deemed Liquidation Event” is defined in the Company’s Amended and Restated Certificate of Incorporation as a merger that results in a change in control or the sale of substantially all the assets of the Company. In the case of a Deemed Liquidation Event, the assets of the Company will be paid in order of liquidation preference to the holders of preferred and common stock. Because certain holders of the Series A Preferred Stock constitute a majority of the Company’s Board of Directors, a potential Deemed Liquidation Event is considered to be outside the control of the Company along with the call provision that can be exercised in one year, resulting in classification of the Series A Preferred Stock as temporary equity. The Company has determined that the warrants should be accounted as a component of stockholders’ equity. On the issuance date, the Company estimated the fair value of the warrants at $1.1 million using the Black-Scholes option pricing model using the following primary assumptions: contractual term of 5.0 years, volatility rate of 79.8%, risk-free interest rate of 1.76% and expected dividend rate of 0%. Based on the warrant’s relative fair value to the fair value of the Series A Preferred, approximately $649,000 of the $1.1 million of aggregate fair value was allocated to the warrants, creating a corresponding preferred stock discount in the same amount. Due to the reduction of allocated proceeds to Series A Preferred, the effective conversion price was approximately $1.1 per share creating a beneficial conversion feature of $807,000. Since the conversion option of the Series A Preferred was immediately exercisable, the beneficial conversion feature was immediately accreted to preferred dividends, resulting in an increase in the carrying value of the Series A Preferred. As of December 31, 2017, the dividends accrued and outstanding were $115,000.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Equity	Note 7 - Stockholders’ Equity Common Stock 2016 Activity During the year ended December 31, 2016, the Company entered into private placement offerings with fourteen investors and issued approximately 1.5 million shares of its common stock and warrants to purchase approximately 1.4 million shares of common stock for $1.4 million. The warrants have a 5-year term and a weighted-average exercise price of $1.68. 100,000 shares issued in this offering are subject to “price protection” for a period of one year. Specifically, in the event the Company issues to any person common stock or their equivalent at a lower price per share than $2.50 (the “Lower Price”), the Company shall, simultaneously with the issuance of such shares, issue that investor a number of additional common shares (the “Additional Shares”) necessary to cause the 100,000 purchased plus the Additional Shares to have a combined average cost per share equal to the Lower Price, provided that in no event shall the Additional Shares exceed 100,000 shares. The price protection feature was analyzed by the Company and the Company determined that such feature was not required to be bifurcated from the common stock and recorded as a derivative as the price protection feature is clearly and closely related to an equity host. In November 2016 the Lower Price protection was triggered and the Company became obligated to issue an additional 100,000 shares of common stock under the arrangement. During the year ended December 31, 2016, the Company also issued 75,000 shares of its subsidiary, CLC, to a consultant, who is also a stockholder for the service provided, and the shares were valued at $1.00 per share based upon the estimated fair value on the date the shares were issued. A related expense of $75,000 was recorded during the year ended December 31, 2016. During the year ended December 31, 2016, 221,875 warrants with a weighted average exercise price of $0.97 were exercised for cash consideration of $215,000. These warrant holders were also granted 221,875 additional warrants in August 2016 with a 5-year term and an exercise price of $2.70 per share. The warrants were accounted for as an inducement and accordingly $378,000 which reflects the fair value of the warrants was recorded as a deemed distribution. The fair value of the warrants was determined using a Black-Scholes model with the following assumptions: risk free rate - 1.14%, volatility - 78.49%, expected term - 5 years, expected dividends - N/A. Stock Options 2016 Equity Plan In the fiscal year ended December 31, 2016, the Company adopted the 2016 Equity Plan, an omnibus equity incentive plan to be administered by the Company’s Board of Directors to which the Company may issue its common shares in connection with grants of stock options to employees and consultants of the Company. The grant date fair value of stock options granted to employees during the years ended December 31, 2017 and 2016 was approximately $4.3 million and $305,000, respectively. The fair value of the Company’s common stock was based upon the publicly quoted price on the date that the final approval of the awards was obtained. The Company does not expect to pay dividends in the foreseeable future so therefore the expected dividend yield is 0%. The expected term for stock options granted with service conditions represents the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach prescribed by the Securities and Exchange Commission’s Staff Accounting Bulletin for “plain vanilla” options. The expected term for stock options granted with performance and/or market conditions represents the estimated period estimated by management by which the performance conditions will be met. The Company obtained the risk-free interest rate from publicly available data published by the Federal Reserve. The Company uses a methodology in estimating its volatility percentage from a computation that was based on a comparison of average volatility rates of similar companies to a computation based on the standard deviation of the Company’s own underlying stock price’s daily logarithmic returns. The fair value of employee options granted in 2017 and 2016 was estimated using the following weighted-average assumptions: For the year Ended December 31, 2017 2016 Exercise price $ 1.85 $ 1.03 Expected stock price volatility 79 % 79 % Risk-free rate of interest 1.61 % 1.37 % Term (years) 3.1 3.7 A summary of option activity under the Company’s employee stock option plan for year ended December 31, 2017 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Employee options granted 4,150,000 1.85 4,160,000 4.5 Exercised (6,000 ) 1.08 11,000 - Forfeited (50,000 ) 1.85 6,000 - Outstanding as of December 31, 2017 5,669,000 $ 1.48 $ 7,793,000 4.3 Options vested and expected to vest as of December 31, 2017 5,669,000 $ 1.48 $ 7,793,000 4.3 Options vested and exercisable as of December 31, 2017 2,444,000 $ 1.19 $ 4,065,000 3.9 In July 2017, in recognition of the service on the Board of Directors, Mr. Feldman and Mr. Kilman each received options to purchase 1,000,000 shares of common stock at an exercise price $1.95 per share, the fair value as of the date of grant, vesting in equal instalments over a four year period starting on July 27, 2017. Also in July 2017 in recognition of his service on the Board of Directors, Mr. Payne received an option to purchase 500,000 shares of common stock at an exercise price $1.95 per share, the fair value as of the date of grant, vesting in equal instalments over a four year period starting on July 27, 2017. A summary of option activity under the Company’s employee stock option plan for year ended December 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,050,000 $ 0.27 $ 757,000 5.1 Employee options granted 525,000 0.97 182,000 5.7 Outstanding as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Options vested and expected to vest as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Options vested and exercisable as of December 31, 2016 687,500 $ 0.36 $ 647,000 3.8 A summary of the activity of options that the Company granted to non-employees for the year ended December 31, 2017 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Non-employee options granted 250,000 1.95 225,000 4.6 Outstanding as of December 31, 2017 3,205,000 $ 0.40 $ 7,847,000 2.4 Options vested and expected to vest as of December 31, 2017 3,205,000 $ 0.40 $ 7,847,000 2.4 Options vested and exercisable as of December 31, 2017 2,317,500 $ 0.38 $ 5,714,000 2.4 A summary of the activity of options that the Company granted to non-employees for the year ended December 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 (as reported) 2,670,000 $ 0.20 $ 2,118,000 4.0 Adjustment to stock options 150,000 0.10 134,000 2.1 Outstanding as of December 31, 2015 (as adjusted) 2,820,000 $ 0.19 $ 2,252,000 3.9 Non-employee options granted 235,000 $ 1.15 $ 46,000 4.9 Non-employee options exercised (100,000 ) 0.11 119,000 - Outstanding as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Options vested and expected to vest as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Options vested and exercisable as of December 31, 2016 1,667,500 $ 0.30 $ 1,660,700 3.3 Estimated future stock-based compensation expense relating to unvested stock options is approximately $2.1 million as of December 31, 2017 and will be amortized over the remaining 2.8 years. Warrants A summary of the status of the Company’s outstanding warrants as of December 31, 2017 and changes during the year then ended is presented below: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9 Issued 1,472,417 1.72 1,666,000 5.0 Outstanding as of December 31, 2017 4,744,292 $ 1.24 $ 7,884,000 3.6 Warrants exercisable as of December 31, 2017 4,494,292 $ 1.24 $ 7,472,000 3.4 A summary of the status of the Company’s outstanding warrants as of December 31, 2016 and changes during the year then ended is presented below: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,850,000 $ 0.31 $ 1,249,000 4.3 Issued 1,643,750 1.82 250,000 4.7 Exercised (221,875 ) 0.97 73,000 4.2 Outstanding as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9 Warrants exercisable as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9 During year ended December 31, 2017, the Company granted 500,000 warrants with an exercise price of $1.20 to a service provider. 250,000 warrants were vested immediately, the other 250,000 warrants will be vested upon performance of the service. Stock-based Compensation Expense Stock-based compensation expense for the year ended December 31, 2017 and 2016 was comprised of the following (in thousands): For the year Ended December 31, 2017 2016 Employee restricted stock awards $ - $ 136 Employee stock option awards 2,423 201 Non-employee option awards 1,766 1,245 Total compensation expense $ 4,189 $ 1,582

Contingencies and Commitments

Contingencies and Commitments	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Commitments	Note 8 - Contingencies and Commitments On March 22, 2016, the Company entered into a lease (the “Lease”) with Hudson View Building #3, LLC (“the “Landlord”), for office and laboratory space located in Yonkers, New York (the “Leased Premise”). The Leased Premise consists of approximately 8,000 square feet. The Lease has a term of 87 months from the lease commencement date, which is the date upon which the Landlord has substantially completed certain interior leasehold improvements to the Leased Premise. The annual rent of the first year of the lease is approximately $208,000, increasing by 1.5% on each anniversary of the lease commencement date. In the event of a termination of the lease following a default by the Company, the Company will be obligated to pay the sum of the rent payable for the remainder of the lease term. The Company moved into the office on May 30, 2017. The Company began paying monthly rent on August 30, 2017. In connection with this lease, the Company obtained an Irrevocable Standby Letter of Credit (the “Letter of Credit”) from Chase Bank for a sum not exceeding $150,000. The Company has deposited this amount with Chase Bank as collateral for the Letter of Credit and recorded the amount as restricted cash and long-term deposit in the consolidated balance sheets. During the year ended December 31, 2017, $100,000 restricted cash was released to the Company. As of December 31, 2017, contractual minimal lease payments are as follows (in thousands): 2018 $ 209 2019 212 2020 215 2021 219 2022 222 Thereafter 377 Total $ 1,454 On February 25, 2009, the Company was granted an exclusive, worldwide, transferable, perpetual license to use certain proprietary technology for the processing of lithium for use in batteries and other fields. Commencing in October 2010, working through a third party, the Company conducted a series of tests to determine if the process worked and, based on the results, initially believed that the process produced lithium, however it did not prove to be commercially feasible and research and development efforts involving this license were abandoned. In exchange for the license, the Company had certain financial, share issuance and royalty obligations if certain sale thresholds were met. However, since contractually agreed thresholds were not met and the technology was not used, the Company negotiated an amendment and release which was finalized in January 2017. Pursuant to the amendment and release, the third party retained two million of the three million total shares from the original license and forfeited the remaining one million shares. The two million shares retained by the third party are subject to customary transfer restrictions for restricted shares. The Company maintained an executive office in Tarrytown, New York. This space was previously provided to the Company without charge by our Executive Chairman, Jerome I. Feldman. Beginning in September 2016 the Company began incurring rent for this space of approximately $5,000 per month, plus taxes and utilities to the current owner Cushman & Wakefield of Pennsylvania, Inc. The lease commenced on May 1, 2016 and terminates on April 30, 2018. The Company has the option to terminate the lease at any time upon two months’ notice. On May 31, 2017, the Company terminated the lease.

Extinguishment of Accounts Paya

Extinguishment of Accounts Payable	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Extinguishment of Accounts Payable	Note 9 - Extinguishment of Accounts Payable During year ended December 31, 2017, the Company issued 62,417 shares of common stock and 62,417 warrants to certain vendors in lieu of $110,000 of outstanding accounts payable. The warrants have a 5-year term and a weighted-average exercise price of $1.76. The fair value of common stock and warrant at the conversion date was approximately $110,000 and $82,000, respectively. The difference of $82,000 was recorded as a loss on extinguishment of accounts payable.

Deferred Tax Assets and Income

Deferred Tax Assets and Income Tax Provision	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Deferred Tax Assets and Income Tax Provision	Note 10 - Deferred Tax Assets and Income Tax Provision The Company had no income tax expense due to operating loss incurred for the years ended December 31, 2017 and 2016. On December 22, 2017, the U.S. government enacted comprehensive tax legislation under the Tax Cuts and Jobs Act (the “Tax Act”), which makes broad changes to the U.S. tax code. Certain changes are applicable to the Company effective January 1, 2018, including but not limited to, reducing the highest U.S. federal corporate statutory tax rate from 35 percent to 21 percent, creating a new limitation on deductible interest expense, eliminating the corporate alternative minimum tax (“AMT”) and modifying the rules related to uses and limitations of net operating loss carryforwards generated in tax years ending after December 31, 2017. Deferred tax impacts from new legislation are accounted for in the period of enactment. As a result of the reduced corporate tax rate to 21 percent, the Company has recorded a decrease related to the gross deferred tax assets by $1.4 million exclusive of the corresponding change in the valuation allowance, for the year ended December 31, 2017. Due to the Company’s position of having a valuation allowance on the net deferred tax assets, there is no net adjustment to deferred tax expense or benefit due to the reduction of the corporate tax rate. The tax effects of temporary differences and tax losses and credit carry forwards that give rise to significant portions of deferred tax assets and liabilities at December 31, 2017 and 2016 are comprised of the following (dollars in thousands): As of December 31, 2017 2016 Deferred tax assets: Net-operating loss carryforward $ 1,523 $ 1,196 Stock based compensation 1,752 1,043 Total Deferred Tax Assets 3,275 2,239 Valuation allowance (3,275 ) (2,239 ) Deferred Tax Asset, Net of Allowance $ - $ - At December 31, 2017, the Company had net operating loss carry forwards for federal and state tax purposes of approximately $5.5 million which expires beginning in 2037. The Company has not performed a detailed analysis to determine whether an ownership change under Section 382 of the IRC has occurred. The effect of a Section 382 ownership change would be the imposition of an annual limitation on the use of net operating loss carryforwards attributable to periods before the change. Any limitation may result in expiration of all, or a portion of the NOL or potential research and development credit carryforwards before utilization. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and taxing strategies in making this assessment. In case the deferred tax assets will not be realized in future periods, the Company has provided a valuation allowance for the full amount of the deferred tax assets at December 31, 2017. The valuation allowance increased by approximately $1.0 million and $1.5 million for the years ended as of December 31, 2017 and 2016, respectively. The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows: For the years ended December 31, 2017 2016 Statutory Federal Income Tax Rate (34.0 )% (34.0 )% State Taxes, Net of Federal Tax Benefit (5.8 )% (5.8 )% Federal tax rate change 11.9 % - % Stock based compensation 3.0 % - % Warrant issued for services 1.4 % - % Loss on extinguishment of accounts payable 0.5 % - % Change in Valuation Allowance 23.0 % 39.8 % Income Taxes Provision (Benefit) 0.0 % 0.0 % The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2017. The Company is in the process of preparing the 2017 federal and state tax returns. Therefore, the Company’s 2017 net operating loss carryovers will not be available to offset future taxable income, if any, until the tax returns are filed.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 11 - Subsequent Events On February 8, 2018, the Company entered into a preferred stock purchase agreement (“Stock Purchase Agreement”) with several accredited and institutional investors, pursuant to which the Company agreed to issue and sell in a private placement 1,950 shares of Series A Preferred Stock, as well as 975,000 warrants to purchase the Company’s common stock, at a purchase price of $1,000 per share, for total gross proceeds of $1.95 million.

Significant and Critical Acco18

Significant and Critical Accounting Policies and Practices (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company’s subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net loss attributable to non-controlling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The Company’s consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value used in estimating the value of warrants, stock-based compensation, accrued expenses and provisions for income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Fair Value Measurement	Fair Value Measurement The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The carrying amounts of cash accounts payable and accrued expenses and advances from related parties approximate fair value as these accounts are largely current and short term in nature.
Cash	Cash As of December 31, 2017 and 2016, substantially all of the Company’s cash was held by major financial institutions and the balance at certain times may exceed the maximum amount insured by the Federal Deposits Insurance Corporation. However, the Company has not experienced losses on these accounts and management believes that the Company is not exposed to significant risks on such accounts.
Property and Equipment	Property and Equipment Lab equipment, leasehold improvements and office equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset, generally three years.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. There were no indicators of impairment for long-lived assets during the years ended December 31, 2017 and 2016.
Fair Value of Preferred Stock	Fair Value of Preferred Stock The fair value of Preferred stock was estimated based upon equivalent common shares that Preferred Stock could have been converted into at the closing price on the purchase date.
Convertible Financial Instruments	Convertible Financial Instruments The Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument. Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
Research and Development	Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations, consultants, the cost of acquiring and manufacturing research trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development
Contingencies	Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.
Loss Per Share	Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options, unvested shares of restricted stock and outstanding common stock purchase warrants because their effect would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at December 31, 2017 and 2016 are as follows: As of December 31, 2017 2016 Warrants to purchase common stock 4,744,292 3,271,875 Options to purchase common stock 8,874,000 4,530,000 Preferred stock to exchange common stock 1,106,807 - Total 14,725,099 7,801,875
Non-Controlling Interests	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Updates (the “ASU”) 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments,

Organization and Operations (Ta

Organization and Operations (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Ownership Interest in Subsidiary Company	Following the sale of CLC’s shares, the ownership is as follows: Stockholder Shares Percentage alpha-En Corporation 9,095,000 90.95 % Non-controlling interests 905,000 9.05 % Total: 10,000,000 100.00 %

Significant and Critical Acco20

Significant and Critical Accounting Policies and Practices (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at December 31, 2017 and 2016 are as follows: As of December 31, 2017 2016 Warrants to purchase common stock 4,744,292 3,271,875 Options to purchase common stock 8,874,000 4,530,000 Preferred stock to exchange common stock 1,106,807 - Total 14,725,099 7,801,875

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The components of property and equipment as of December 31, 2017 and 2016, at cost are (dollars in thousands): Useful Life (Years) December 31, 2017 December 31, 2016 Lab equipment 3 $ 173 $ 173 Office furniture and equipment 3 31 12 Leasehold improvement 7 374 368 Gross property and equipment 578 553 Less: Accumulated depreciation and amortization (77 ) (12 ) Property and equipment, net $ 501 $ 541

Temporary Equity (Tables)

Temporary Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Temporary Equity [Abstract]
Schedule of Temporary Equity	The following table summarizes the Company’s Series A Preferred Stock activities for the year ended December 31, 2017 (dollars in thousands): Series A Preferred Stock Shares Amount Total temporary equity as of December 31, 2016 - $ - Proceeds from sale of Series A preferred stock 1,670 1,670 Conversion of advances into preferred stock 150 150 Beneficial conversion feature of Series A preferred stock - (807 ) Deemed dividends related to beneficial conversion feature of Series A preferred stock - 807 Accrued Series A dividends 115 115 Deemed dividend on Series A preferred stock - 649 Fair Value of common stock warrant issued with Series A preferred stock - (649 ) Total temporary equity as of December 31, 2017 1,935 $ 1,935

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Schedule of Fair Value of Assumptions	The fair value of employee options granted in 2017 and 2016 was estimated using the following weighted-average assumptions: For the year Ended December 31, 2017 2016 Exercise price $ 1.85 $ 1.03 Expected stock price volatility 79 % 79 % Risk-free rate of interest 1.61 % 1.37 % Term (years) 3.1 3.7
Schedule of Warrants Outstanding	A summary of the status of the Company’s outstanding warrants as of December 31, 2017 and changes during the year then ended is presented below: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9 Issued 1,472,417 1.72 1,666,000 5.0 Outstanding as of December 31, 2017 4,744,292 $ 1.24 $ 7,884,000 3.6 Warrants exercisable as of December 31, 2017 4,494,292 $ 1.24 $ 7,472,000 3.4 A summary of the status of the Company’s outstanding warrants as of December 31, 2016 and changes during the year then ended is presented below: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,850,000 $ 0.31 $ 1,249,000 4.3 Issued 1,643,750 1.82 250,000 4.7 Exercised (221,875 ) 0.97 73,000 4.2 Outstanding as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9 Warrants exercisable as of December 31, 2016 3,271,875 $ 1.02 $ 2,000,000 3.9
Schedule of Stock-based Compensation Expense	Stock-based compensation expense for the year ended December 31, 2017 and 2016 was comprised of the following (in thousands): For the year Ended December 31, 2017 2016 Employee restricted stock awards $ - $ 136 Employee stock option awards 2,423 201 Non-employee option awards 1,766 1,245 Total compensation expense $ 4,189 $ 1,582
Employee Stock Option Awards [Member]
Schedule of Stock Options, Activity	A summary of option activity under the Company’s employee stock option plan for year ended December 31, 2017 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Employee options granted 4,150,000 1.85 4,160,000 4.5 Exercised (6,000 ) 1.08 11,000 - Forfeited (50,000 ) 1.85 6,000 - Outstanding as of December 31, 2017 5,669,000 $ 1.48 $ 7,793,000 4.3 Options vested and expected to vest as of December 31, 2017 5,669,000 $ 1.48 $ 7,793,000 4.3 Options vested and exercisable as of December 31, 2017 2,444,000 $ 1.19 $ 4,065,000 3.9 A summary of option activity under the Company’s employee stock option plan for year ended December 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,050,000 $ 0.27 $ 757,000 5.1 Employee options granted 525,000 0.97 182,000 5.7 Outstanding as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Options vested and expected to vest as of December 31, 2016 1,575,000 $ 0.50 $ 1,264,000 4.7 Options vested and exercisable as of December 31, 2016 687,500 $ 0.36 $ 647,000 3.8
Non Employee Stock Option Awards [Member]
Schedule of Stock Options, Activity	A summary of the activity of options that the Company granted to non-employees for the year ended December 31, 2017 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Non-employee options granted 250,000 1.95 225,000 4.6 Outstanding as of December 31, 2017 3,205,000 $ 0.40 $ 7,847,000 2.4 Options vested and expected to vest as of December 31, 2017 3,205,000 $ 0.40 $ 7,847,000 2.4 Options vested and exercisable as of December 31, 2017 2,317,500 $ 0.38 $ 5,714,000 2.4 A summary of the activity of options that the Company granted to non-employees for the year ended December 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 (as reported) 2,670,000 $ 0.20 $ 2,118,000 4.0 Adjustment to stock options 150,000 0.10 134,000 2.1 Outstanding as of December 31, 2015 (as adjusted) 2,820,000 $ 0.19 $ 2,252,000 3.9 Non-employee options granted 235,000 $ 1.15 $ 46,000 4.9 Non-employee options exercised (100,000 ) 0.11 119,000 - Outstanding as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Options vested and expected to vest as of December 31, 2016 2,955,000 $ 0.27 $ 3,053,000 3.2 Options vested and exercisable as of December 31, 2016 1,667,500 $ 0.30 $ 1,660,700 3.3

Contingencies and Commitments (

Contingencies and Commitments (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contractual Minimal Lease Payments	As of December 31, 2017, contractual minimal lease payments are as follows (in thousands): 2018 $ 209 2019 212 2020 215 2021 219 2022 222 Thereafter 377 Total $ 1,454

Deferred Tax Assets and Incom25

Deferred Tax Assets and Income Tax Provision (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	As of December 31, 2017 2016 Deferred tax assets: Net-operating loss carryforward $ 1,523 $ 1,196 Stock based compensation 1,752 1,043 Total Deferred Tax Assets 3,275 2,239 Valuation allowance (3,275 ) (2,239 ) Deferred Tax Asset, Net of Allowance $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	The expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with actual tax expense (benefit) as follows: For the years ended December 31, 2017 2016 Statutory Federal Income Tax Rate (34.0 )% (34.0 )% State Taxes, Net of Federal Tax Benefit (5.8 )% (5.8 )% Federal tax rate change 11.9 % - % Stock based compensation 3.0 % - % Warrant issued for services 1.4 % - % Loss on extinguishment of accounts payable 0.5 % - % Change in Valuation Allowance 23.0 % 39.8 % Income Taxes Provision (Benefit) 0.0 % 0.0 %

Organization and Operations (De

Organization and Operations (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2017	Mar. 29, 2017	Dec. 31, 2016	Sep. 30, 2014
Franchisor Disclosure [Line Items]
Common stock share authorized	57,000,000		57,000,000
Common stock, par value	$ 0.01		$ 0.01
Common Class B [Member]
Franchisor Disclosure [Line Items]
Common stock share authorized	1,000,000	1,000,000	1,000,000
Common stock, par value		$ 0.01
Series A Preferred [Member] | February 8, 2018 [Member] | Minimum [Member]
Franchisor Disclosure [Line Items]
Preferred stock shares authorized	2,000
Series A Preferred [Member] | February 8, 2018 [Member] | Maximum [Member]
Franchisor Disclosure [Line Items]
Preferred stock shares authorized	5,000
Board of Directors [Member]
Franchisor Disclosure [Line Items]
Issued and outstanding voting stock, percentage		75.00%
Capital stock authorized		60,000,000
Common stock share authorized		57,000,000
Common stock, par value		$ 0.01
Preferred stock shares authorized		2,000,000
Preferred stock, par value		$ 0.01
Clean Lithium Corporation [Member]
Franchisor Disclosure [Line Items]
Capital				$ 100

Organization and Operations - S

Organization and Operations - Schedule of Ownership Interest in Subsidiary Company (Details)	Dec. 31, 2017shares
Equity method investment, ownership percentage	100.00%
Clean Lithium Corporation [Member]
Shares, outstanding	10,000,000
Equity method investment, ownership percentage	100.00%
Alpha-En Corporation [Member] | Clean Lithium Corporation [Member]
Shares, outstanding	9,095,000
Equity method investment, ownership percentage	90.95%
Noncontrolling Interest [Member] | Clean Lithium Corporation [Member]
Shares, outstanding	905,000
Equity method investment, ownership percentage	9.05%

Going Concern and Liquidity (De

Going Concern and Liquidity (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 20,276	$ 13,749
Negative working capital	834
Net loss	6,911	3,797
Net cash provided by operating activities, continuing operations	$ 1,986	$ 1,473

Significant and Critical Acco29

Significant and Critical Accounting Policies and Practices (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Ownership percentage	100.00%
Estimated useful life	3 years
Impairment for long-lived assets

Significant and Critical Acco30

Significant and Critical Accounting Policies and Practices - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	14,725,099	7,801,875
Stock Option [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	8,874,000	4,530,000
Preferred Stock [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,106,807
Warrant [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,744,292	3,271,875

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 65	$ 12

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Gross property and equipment	$ 578	$ 553
Less: Accumulated depreciation	(77)	(12)
Property and equipment, net	$ 501	541
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Gross property and equipment	$ 173	173
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Gross property and equipment	$ 31	12
Leasehold Improvement [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Gross property and equipment	$ 374	$ 368

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	May 17, 2017	Feb. 23, 2017	Dec. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Repayments of related party debt			$ 32	$ 70
Conversion of stock shares converted			150
Advances from related parties outstanding amount			$ 308	78
Remaining liability			57
Stock option vest		150,000
Number of common stock issued for services, values				(75)
Second Year [Member]
Related Party Transaction [Line Items]
Stock option vest		150,000
Third Year [Member]
Related Party Transaction [Line Items]
Stock option vest		200,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments related to tax withholding for share-based compensation				$ 198
Preferred Stock [Member]
Related Party Transaction [Line Items]
Conversion into stock			150
Steven M. Payne [Member]
Related Party Transaction [Line Items]
Due from related party			150
Repayments of related party debt			32
Conversion into stock	$ 50
Jerome I. Feldman [Member]
Related Party Transaction [Line Items]
Due from related party			100
Repayments of related party debt			32
Conversion into stock	50
Jim Kilman [Member]
Related Party Transaction [Line Items]
Due from related party			150
Repayments of related party debt			32
Conversion into stock	$ 50
Steven M. Fludder [Member]
Related Party Transaction [Line Items]
Due from related party			12
Repayments of related party debt			$ 32
Mr Wasserman [Member]
Related Party Transaction [Line Items]
Stock option to purchase common stock		500,000
Exercise price per share		$ 1.10
Officers compensation		$ 5
Consultant [Member] | Clean Lithium Corporation [Member]
Related Party Transaction [Line Items]
Number of common stock issued for services, shares				75,000
Shares issued price per share				$ 1
Number of common stock issued for services, values				$ 75

Temporary Equity (Details Narra

Temporary Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	May 17, 2017	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par or stated value per share		$ 0.01	$ 0.01
Common stock, par or stated value per share		0.01	0.01
Warrants exercise price		$ 1.20	$ 0.97
Number of preferred stock converted into shares of common stock, shares		150
Warrants fair value			$ 378
Contractual term			5 years
Volatility rate			78.49%
Risk-free interest rate			1.14%
Steven M. Payne [Member]
Number of preferred stock converted into shares of common stock	$ 50
Jerome I. Feldman [Member]
Number of preferred stock converted into shares of common stock	50
Jim Kilman [Member]
Number of preferred stock converted into shares of common stock	$ 50
Series A Preferred Stock [Member]
Number of preferred stock shares issued	1,820
Preferred stock, par or stated value per share	$ 0.01
Warrant purchase of common stock, shares	910,000
Common stock, par or stated value per share	$ 0.01
Purchase price per share	$ 1,000
Gross proceeds from issuance of preferred stock	$ 1,820
Warrants term	5 years
Warrants exercise price	$ 2
Preferred stock dividend rate	10.00%
Original issue price	$ 1,000
Number of preferred stock converted into shares of common stock, shares	572
Warrants fair value	$ 1,100
Contractual term	5 years
Volatility rate	79.80%
Risk-free interest rate	1.76%
Expected dividend rate	0.00%
Preferred stock fair value	$ 649
Preferred stock conversion price	$ 1.1
Preferred stock conversion basis	Due to the reduction of allocated proceeds to Series A Preferred, the effective conversion price was approximately $1.1 per share
Preferred stock beneficial conversion feature	$ 807
Dividend accrued and outstanding		$ 115

Temporary Equity - Schedule of

Temporary Equity - Schedule of Temporary Equity (Details) - Series A Preferred Stock [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)shares
Total temporary equity, beginning
Total temporary equity, shares beginning | shares
Proceeds from sale of Series A preferred stock	$ 1,670
Proceeds from sale of Series A preferred stock, shares | shares	1,670
Conversion of advances into preferred stock	$ 150
Conversion of advances into preferred stock, shares | shares	150
Beneficial conversion feature of Series A preferred stock	$ (807)
Deemed dividends related to beneficial conversion feature of Series A preferred stock	$ 807
Accrued Series A dividends, shares | shares	115
Accrued Series A dividends	$ 115
Deemed dividend on Series A preferred stock	649
Fair Value of common stock warrant issued with Series A preferred stock	(649)
Total temporary equity, ending	$ 1,935
Total temporary equity, shares ending | shares	1,935

Stockholders' (Deficit) Equity

Stockholders' (Deficit) Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jul. 01, 2017	Nov. 30, 2016	Aug. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Number of additional shares of common stock issued under arrangement		100,000
Number of common stock issued for service, value					$ (75)
Number of warrant exercised for cash consideration					221,875
Exercise price of warrant				$ 1.20	$ 0.97
Number of warrant exercised for cash consideration, value					$ 215
Fair value of warrants					$ 378
Warrant risk-free interest rate					1.14%
Warrant volatility rate					78.49%
Warrant contractual term					5 years
Expected dividends					0.00%
Fair value of stock option granted				$ 4,300	$ 305
Stock based compensation expense relating to unvested				$ 2,100
Amortized period				2 years 9 months 18 days
Warrants granted for service				500,000
Number of warrants vested immediately				250,000
Number of other warrants will be vested upon performance of services				250,000
Mr. Feldman and Mr. Kilman [Member]
Number of options to purchase shares of common stock	1,000,000
Common stock options exercise price	$ 1.95
Options granted vesting period	4 years
Mr. Payne [Member]
Number of options to purchase shares of common stock	500,000
Common stock options exercise price	$ 1.95
Options granted vesting period	4 years
Clean Lithium Corporation [Member] | Consultant [Member]
Exercise price per shares					$ 1
Number of common stock issued for service					75,000
Number of common stock issued for service, value					$ 75
Private Placement [Member] | Investor [Member]
Number of common shares					1,500,000
Warrant purchase of common stock, shares					1,400,000
Warrant to purchase of common stock					$ 1,400
Warrant term					5 years
Warrant, weighted average exercise price					$ 1.68
Exercise price per shares					$ 2.50
Additional Shares [Member] | Private Placement [Member] | Investor [Member]
Number of common shares					100,000
Price Protection [Member] | Private Placement [Member] | Investor [Member]
Warrant purchase of common stock, shares					100,000
Additional Warrants [Member] | Warrant Holders [Member]
Warrant term			5 years
Exercise price of warrant			$ 2.70
Number of warrants granted			221,875

Stockholders' (Deficit) Equit37

Stockholders' (Deficit) Equity - Schedule of Fair Value of Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Exercise price	$ 1.85	$ 1.03
Expected stock price volatility	79.00%	79.00%
Risk-free rate of interest	1.61%	1.37%
Term (years)	3 years 1 month 6 days	3 years 8 months 12 days

Stockholders' (Deficit) Equit38

Stockholders' (Deficit) Equity - Schedule of Stock Options, Activity (Details) - USD ($)	Feb. 23, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Shares, Options vested and expected to vest	150,000
Weighted Average Exercise Price, Outstanding, Beginning Balance		$ 1.03
Weighted Average Exercise Price, Outstanding, Ending Balance		$ 1.85	$ 1.03
Employee Stock Option Awards [Member]
Number of Shares, Outstanding, Beginning Balance		1,575,000	1,050,000
Number of Shares, Options granted		4,150,000	525,000
Number of Shares, Option Exercised		(6,000)
Number of Shares, Forfeited		(50,000)
Number of Shares, Outstanding, Ending Balance		5,669,000	1,575,000	1,050,000
Number of Shares, Options vested and expected to vest		5,669,000	1,575,000
Number of Shares, Options vested and exercisable		2,444,000	687,500
Weighted Average Exercise Price, Outstanding, Beginning Balance		$ 0.50	$ 0.27
Weighted Average Exercise Price, Options granted		1.85	0.97
Weighted Average Exercise Price, Options Exercised		1.08
Weighted Average Exercise Price, Forfeited		1.85
Weighted Average Exercise Price, Outstanding, Ending Balance		1.48	0.50	$ 0.27
Weighted Average Exercise Price, Options vested and expected to vest		1.48	0.50
Weighted Average Exercise Price, Options vested and exercisable		$ 1.19	$ 0.36
Intrinsic Value, Outstanding, Beginning Balance		$ 1,264,000	$ 757,000
Intrinsic Value, Options granted		4,160,000	182,000
Intrinsic Value, Options exercised		11,000
Intrinsic Value, Forfeited		6,000
Intrinsic Value, Outstanding, Ending Balance		7,793,000	1,264,000	$ 757,000
Intrinsic Value, Options vested and expected to vest		7,793,000	1,264,000
Intrinsic Value, Options vested and exercisable		$ 4,065,000	$ 647,000
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance		4 years 8 months 12 days	5 years 1 month 6 days
Weighted Average Remaining Contractual Life (in years), Options granted		4 years 6 months	5 years 8 months 12 days
Weighted Average Remaining Contractual Life (in years), Options Exercised		0 years
Weighted Average Remaining Contractual Life (in years), Forfeited		0 years
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance		4 years 3 months 19 days	4 years 8 months 12 days
Weighted Average Remaining Contractual Life (in years), Options vested and expected to vest		4 years 3 months 19 days	4 years 8 months 12 days
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable		3 years 10 months 25 days	3 years 9 months 18 days
Non Employee Stock Option Awards [Member]
Number of Shares, Outstanding, Beginning Balance		2,955,000	2,820,000	2,670,000
Number of Shares, Adjustment to stock options				150,000
Number of Shares, Options granted		250,000	235,000
Number of Shares, Option Exercised			(100,000)
Number of Shares, Outstanding, Ending Balance		3,205,000	2,955,000	2,820,000
Number of Shares, Options vested and expected to vest		3,205,000	2,955,000
Number of Shares, Options vested and exercisable		2,317,000	1,667,500
Weighted Average Exercise Price, Outstanding, Beginning Balance		$ 0.27	$ 0.19	$ 0.20
Weighted Average Exercise Price, Adjustment to stock options				0.10
Weighted Average Exercise Price, Options granted		1.95	1.15
Weighted Average Exercise Price, Options Exercised			0.11
Weighted Average Exercise Price, Outstanding, Ending Balance		0.40	0.27	$ 0.19
Weighted Average Exercise Price, Options vested and expected to vest		0.40	0.27
Weighted Average Exercise Price, Options vested and exercisable		$ 0.38	$ 0.30
Intrinsic Value, Outstanding, Beginning Balance		$ 3,053,000	$ 2,252,000	$ 2,118,000
Intrinsic Value, Adjustment to stock options				134,000
Intrinsic Value, Options granted		225,000	46,000
Intrinsic Value, Options exercised			119,000
Intrinsic Value, Forfeited			3,053,000
Intrinsic Value, Outstanding, Ending Balance		7,847,000	3,053,000	$ 2,252,000
Intrinsic Value, Options vested and expected to vest		7,847,000	$ 1,660,700
Intrinsic Value, Options vested and exercisable		$ 5,714,000
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance		3 years 2 months 12 days	3 years 10 months 25 days	4 years
Weighted Average Remaining Contractual Life (in years), Adjustment to stock options				2 years 1 month 6 days
Weighted Average Remaining Contractual Life (in years), Options granted		4 years 7 months 6 days	4 years 10 months 25 days
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance		2 years 4 months 24 days	3 years 2 months 12 days	3 years 10 months 25 days
Weighted Average Remaining Contractual Life (in years), Options vested and expected to vest		2 years 4 months 24 days	3 years 2 months 12 days
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable		2 years 4 months 24 days	3 years 3 months 19 days

Stockholders' (Deficit) Equit39

Stockholders' (Deficit) Equity - Schedule of Warrants Outstanding (Details) - Warrant [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Warrant, Beginning	3,271,875	1,850,000
Number of Warrant, Issued	1,472,417	1,643,750
Number of Warrant, Exercised		(221,875)
Number of Warrant, Ending	4,744,292	3,271,875
Number of Warrants, Warrants exercisable	4,494,292	3,271,875
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 1.02	$ 0.31
Weighted Average Exercise Price, Issued	1.72	1.82
Weighted Average Exercise Price, Exercised		0.97
Weighted Average Exercise Price, Outstanding, Ending Balance	1.24	1.02
Weighted Average Exercise Price, Warrants exercisable	$ 1.24	$ 1.02
Intrinsic Value, Outstanding, Beginning Balance	$ 2,000	$ 1,249
Intrinsic Value, Issued	1,666	250
Intrinsic Value, Exercised		73
Intrinsic Value, Outstanding, Ending Balance	7,884	2,000
Intrinsic Value, Warrants exercisable	$ 7,472	$ 2,000
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance	3 years 10 months 25 days	4 years 3 months 19 days
Weighted Average Remaining Contractual Life (in years), Issued	5 years	4 years 8 months 12 days
Weighted Average Remaining Contractual Life (in years), Exercised		4 years 2 months 12 days
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance	3 years 7 months 6 days	3 years 10 months 25 days
Weighted Average Remaining Contractual Life (in years), Warrants exercisable	3 years 4 months 24 days	3 years 10 months 25 days

Stockholders' (Deficit) Equit40

Stockholders' (Deficit) Equity - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation	$ 4,189	$ 1,582
Employee Restricted Stock Awards [Member]
Share-based Compensation		136
Employee Stock Option Awards [Member]
Share-based Compensation	2,423	201
Non Employee Stock Option Awards [Member]
Share-based Compensation	$ 1,766	$ 1,245

Contingencies and Commitments41

Contingencies and Commitments (Details Narrative) $ in Thousands	Mar. 22, 2016USD ($)ft²	Feb. 25, 2009	Dec. 31, 2017USD ($)
Area of lease | ft²	8,000
Lease term	87 months
Operating lease rent	$ 208
Percentage of increase in lease rent	1.50%
Line of credit facility, maximum borrowing capacity			$ 150
Release of restricted cash			100
Description of commitments		Pursuant to the amendment and release, the third party retained two million of the three million total shares from the original license and forfeited the remaining one million shares.
Jerome I. Feldman [Member]
Operating lease rent			$ 5
Lease expiration date			Apr. 30, 2018

Contingencies and Commitments -

Contingencies and Commitments - Schedule of Contractual Minimal Lease Payments (Details) $ in Thousands	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 209
2,019	212
2,020	215
2,021	219
2,022	222
Thereafter	377
Total	$ 1,454

Extinguishment of Accounts Pa43

Extinguishment of Accounts Payable (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Weighted-average exercise price	$ 1.20	$ 0.97
Fair value of warrant		$ 378
Debt extinguishment loss	$ (82)
Vendors in Lieu [Member]
Issued shares of common stock in lieu of outstanding accounts payable	62,417
Issued shares of warrants in lieu of outstanding accounts payable	62,417
Issued shares of common stock and warrants in lieu of outstanding accounts payable	$ 110
Warrants term	5 years
Weighted-average exercise price	$ 1.76
Fair value of common stock	$ 110
Fair value of warrant	82
Debt extinguishment loss	$ 82

Deferred Tax Assets and Incom44

Deferred Tax Assets and Income Tax Provision (Details Narrative) - USD ($) $ in Thousands	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
U.S federal corporate tax rate	35.00%	34.00%	34.00%
U.S federal corporate tax reduced rate	21.00%
Valuation allowance, deferred tax asset, increase amount	$ 1,400	$ 1,000	$ 1,500
Net operating loss carry forwards		$ 5,500
Operating loss carry forwards, expiration term		expires beginning in 2037

Deferred Tax Assets and Incom45

Deferred Tax Assets and Income Tax Provision - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Net-operating loss carryforward	$ 1,523	$ 1,196
Stock based compensation	1,752	1,043
Total Deferred Tax Assets	3,275	2,239
Valuation allowance	(3,275)	(2,239)
Deferred Tax Asset, Net of Allowance

Deferred Tax Assets and Incom46

Deferred Tax Assets and Income Tax Provision - Schedule of Effective Income Tax Rate Reconciliation (Details)	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Statutory Federal Income Tax Rate	(35.00%)	(34.00%)	(34.00%)
State Taxes, Net of Federal Tax Benefit		(5.80%)	(5.80%)
Federal tax rate change		11.90%	0.00%
Stock based compensation		3.00%	0.00%
Warrant issued for services		1.40%	0.00%
Loss on extinguishment of accounts payable		0.50%	0.00%
Change in Valuation Allowance		23.00%	39.80%
Income Taxes Provision (Benefit)		0.00%	0.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Series A Preferred Stock [Member] - USD ($) $ / shares in Units, $ in Thousands	Feb. 08, 2018	May 17, 2017
Warrant to purchase of common stock		910,000
Subsequent Event [Member] | Stock Purchase Agreement [Member]
Number of shares issued	1,950
Warrant to purchase of common stock	975,000
Purchase price per share	$ 1,000
Total gross proceeds	$ 1,950